Evidence map›Paper›PMID 12802276›Full record

ArticleOncogene2003

Regulation of Hoxb2 by APL-associated PLZF protein.

Sarah Ivins, Kieran Pemberton, Fabien Guidez, Louise Howell, Robb Krumlauf, Arthur Zelent

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. RARα-PLZF oncogene inhibits C/EBPα function in myeloid cells.Proceedings of the National Academy of Sciences of the United States of America · 2013
    Article
  8. Article
  9. Transcriptional networks in liver and intestinal development.Cold Spring Harbor perspectives in biology · 2012
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Repression of kit expression by Plzf in germ cells.Molecular and cellular biology · 2007
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Sarah IvinsLeukaemia Research Fund Centre at the Institute of Cancer Research, Chester Beatty Laboratories, Fulham Road, London SW3 6JB, UK.
Kieran Pemberton
Fabien Guidez
Louise Howell
Robb Krumlauf
Arthur Zelent
Institute of Cancer Research · GBStowers Institute for Medical Research · USBlood Cancer UK · GB

Funding

The PLZF Protein of t(11;17)-Promyelocytic LeukemiaR01CA059936 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LICHT, JONATHAN · 1993 to 2007
$2.9M
NCI NIH HHS CA59936
6 · The paper itself

Abstract

The PLZF gene is translocated in a subset of all-trans-retinoic acid resistant acute promyelocytic leukaemia (APL) cases, encodes a DNA binding transcription factor and is expressed highly in haematopoietic progenitor cells as well-developing central nervous system (CNS). The spatially restricted and temporally dynamic pattern of PLZF expression in the developing CNS suggested that it might play a role in the circuitry regulating hindbrain segmentation. We have now identified a PLZF binding site (PLZF-RE) in an enhancer region of Hoxb2 that itself is required for directing high-level expression in rhombomers 3 and 5 of the developing hindbrain. The wild-type r3/r5 enhancer linked to a heterologous promoter was responsive to regulation by PLZF, and this activity was lost in variants containing a mutated PLZF-RE. Compared with the wild-type protein, the binding of the APL-associated reciprocal RARalpha-PLZF fusion to PLZF-RE was much stronger, suggesting that the N-terminal PLZF sequences missing from the fusion may play a role in the regulation of DNA binding. Consistent with this, the N-terminal POZ domain was required for cooperative binding of PLZF to a multimerized PLZF-RE. In the context of the r3/r5 enhancer, the PLZF-RE cooperated for PLZF binding with an additional A/T-rich motif positioned downstream of the PLZF-RE. This A/T motif was previously shown to be essential for the regulation of Hoxb2 expression in r3 and r5 in cooperation with another Krüppel-like zinc finger protein Krox 20. The presence of both the PLZF-RE and the A/T-rich motif was required for a maximal effect of PLZF on a heterologous promoter and was essential in vivo to direct the expression of a lacZ reporter in the chick neural tube. Hence, both PLZF and Krox20 cooperate with a common A/T motif in mediating in vivo activity of the Hoxb2 enhancer. Our findings indicate that Hoxb2 is a direct target for regulation by PLZF in the developing CNS and suggest that deregulation of Hox gene expression may contribute to APL pathogenesis.

Indexed as

Gene Expression RegulationAnimalsBinding SitesChick EmbryoDNADNA-Binding ProteinsEnhancer Elements, GeneticHematopoiesisHomeodomain ProteinsHumansKruppel-Like Transcription FactorsLeukemia, Promyelocytic, AcutePromyelocytic Leukemia Zinc Finger ProteinReceptors, Retinoic AcidRepressor ProteinsRetinoic Acid Receptor alphaDNADNA-Binding ProteinsHomeodomain ProteinsHOXB2 protein, humanKruppel-Like Transcription FactorsPromyelocytic Leukemia Zinc Finger ProteinRARA protein, humanReceptors, Retinoic AcidRepressor ProteinsRetinoic Acid Receptor alphaTranscription FactorsZBTB16 protein, human

Identifiers

PMID12802276
OpenAlexW2000700820

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.